Candidiasis, aspergillosis and other invasive mycoses in recipients of solid organ transplants;Candidiasis, aspergilosis y otras micosis invasoras en receptores de trasplantes de órgano sólido

Revista Iberoamericana de Micologia

Volumn 28, Issue 3, 2011, Pages 110-119

  Quindós, Guillermo ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Aspergillosis; Candidiasis; Cryptococcosis; Filamentous fungi; Fungal infections; Hyalohyphomycoses; Moulds; Mucormycoses; Mycoses; Pheohyphomycoses; Scedosporioses; Transplant recipients; Zygomycoses

Indexed keywords

ASPERGILLUS; CANDIDA; CRYPTOCOCCOSIS; FUNGUS; GRAFT RECIPIENT; HUMAN; HYALOHYPHOMYCOSIS; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; MOULD; MUCORMYCOSIS; MYCOSIS; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PHAEOHYPHOMYCOSIS; PSEUDALLESCHERIASIS; SHORT SURVEY; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDEMIA; COMORBIDITY; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; FOLLOW-UP STUDIES; FUNGEMIA; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MYCOLOGY; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PREMEDICATION;

ASPERGILLUS; CANDIDA; FUNGI;

EID: 79959372157     PISSN: 11301406     EISSN: 21739188     Source Type: Journal    
DOI: 10.1016/j.riam.2011.06.002     Document Type: Short Survey

References (139)

1. Abad A., Fernández-Molina J.V., BikandiJ, Ramirez A., Margareto J., Sendino J., et al. What makes Aspergillus fumigatus a successful pathogen?. Genes and molecules involved in invasive aspergillosis. Rev Iberoam Micol. 2010, 27:155-182.
2. Aguado J.M., Ayats J. Role of anidulafungin in solid organ transplant recipients. Enferm Infecc Microbiol Clin. 2008, 26:29-34.
3. Aguado JM, Ruiz I, Muñoz P, Mensa J, Almirante B, Vázquez L, et al. Recomenda- ciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por le- vaduras de la Sociedad Española de Microbiología Clínica y Enfermedades Infec- ciosas (SEIMC). Actualización 2010. Enferm Infecc Microbiol Clin. 2011; 29. En prensa.
4. Alastruey-Izquierdo A., Castelli M.V., Cuesta I., Zaragoza O., Monzon A., Mellado E., et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect. 2009, 15:71-76.
5. Alastruey-Izquierdo A., Cuesta I., Houbraken J., Cuenca-Estrella M., Monzon A. Ro- driguez-Tudela JL. In vitro activity of nine antifungal agents against clinical isola tes of Aspergillus calidoustus. Med Mycol. 2010, 48:97-102.
6. Alastruey-Izquierdo A., Cuesta I., Walther G., Cuenca-Estrella M., Rodriguez-Tudela J.L. Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. Antimicrob. Agents Chemother. 2010, 54:3058-3060.
7. Albano L., Bretagne S., Mamzer-Bruneel M.F., Kacso I., Desnos-Ollivier M., Guerrini P., et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis. 2009, 48:194-202.
8. Alexander B.D., Schell W.A., Siston A.M., Rao C.Y., Bower W.A., Balajee S.A., et al. Fatal Apophysomyces elegans infection transmitted by deceased donor renal allografts. Am J Transplant. 2010, 10:2161-2167.
9. Alexander B.D., Smith P.B., Davis R.D., Perfect J.R., Reller L.B. The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung trans plantation. J Clin Microbiol. 2010, 48:4083-4088.
10. Almirante B., Rodriguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infec tion: results from population-based surveillance, Barcelona. Spain, from 2002 to 2003. J Clin Microbiol. 2005, 43:1829-1835.
11. Alsharif M., Cameron S.E., YoungJA, Savik K., HenriksenJC, Gulbahce H.E., et al. Time trends in fungal infections as a cause of death in hematopoietic stem cell trans plant recipients: an autopsy study. Am J Clin Pathol. 2009, 132:746-755.
12. Alvarez E., Stchigel A.M., Cano J., Sutton D.A., Fothergill A.W., ChanderJ, et al. Molecu lar phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: Proposal of three new species. Rev Iberoam Micol. 2010, 27:80-89.
13. Anane S., Attouchi H. Microsporidiosis: epidemiology, clinical data and therapy. Gastroenterol Clin Biol. 2010, 34:450-464.
14. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Schonheyder H.C., KnudsenJD, Jensen I.M., et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect. 2008, 14:487-494.
15. Arendrup M.C., Rodriguez-Tudela J.L., Park S., Garcia-Effron G., Delmas G. Cuenca- Estrella M, et al. Echinocandin Susceptibility Testing of Candida spp. Using EU- CAST EDef 7. 1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots. Antimi crob Agents Chemother. 2011, 55:1580-1587.
16. Arthurs S.K., Eid A.J., Deziel P.J., Marshall W.F., Cassivi S.D., Walker R.C., et al. The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant. 2009, 24:341-348.
17. Ashkenazi-Hoffnung L., Bilavsky E., Avitzur Y., Amir J. Successful treatment of cu taneous zygomycosis with intravenous amphotericin B followed by oral posaco- nazole in a multivisceral transplant recipient. Transplantation. 2010, 90:1133-1135.
18. Auberger J., Lass-Florl C., Ulmer H., Nogler-Semenitz E., Clausen J., Gunsilius E., et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2008, 88:508-515.
19. Ayats J., Martín-Mazuelos E., Pemán J., Quindós G., Sánchez F., García-Rodríguez J., et al. Recomendaciones sobre el diagnóstico de la infección fúngica invasora de la Sociedad Española de Microbiología Clínica y Enfermedades Infecciosas (SEIMC) 39.e1-39. Actualización 2010. Enferm Infecc Microbiol Clin. 2011, 29:e15.
20. Baddley J.W, Andes D.R., Marr K.A., Kontoyiannis D.P., Alexander B.D., Kauffman C.A., et al. Factors associated with mortality in transplant patients with invasive aspergi llosis. Clin Infect Dis. 2010, 50:1559-1567.
21. Baddley J.W., Marr K.A., Andes D.R., Walsh T.J., Kauffman C.A., Kontoyiannis D.P., et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009, 47:3271-3275.
22. Balajee S.A., Borman A.M., Brandt M.E., Cano J., Cuenca-Estrella M., Dannaoui E., et al. Sequence-based identification of Aspergillus. Fusarium, and muco rales species in the clinical mycology laboratory: where are we and where should we go from here?. J Clin Microbiol. 2009, 47:877-884.
23. Balajee S.A., Kano R., Baddley J.W., Moser S.A., Marr K.A., Alexander B.D., et al. Molecu lar identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009, 47:3138-3141.
24. Bitar D., Van C.D., Lanternier F., Dannaoui E., Che D., Dromer F., et al. Increasing inci dence of zygomycosis (mucormycosis). France, 1997-2006. Emerg Infect Dis. 2009, 15:1395-1401.
25. Blum G., Perkhofer S., Grif K., Mayr A., Kropshofer G., Nachbaur D., et al. A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: mo lecular typing of environmental and clinical isolates. Clin Microbiol Infect. 2008, 14:1146-1151.
26. Bonatti H., Pruett T.L., Brandacher G., Hagspiel K.D., Housseini A.M., Sifri C.D., et al. Pneumonia in solid organ recipients: spectrum of pathogens in 217 episodes. Transplant Proc. 2009, 41:371-374.
27. Bravo D., Blanquer J., Tormo M., Aguilar G., Borras R., Solano C., et al. Diagnostic ac curacy and potential clinical value of the LightCycler SeptiFast assay in the ma nagement of bloodstream infections occurring in neutropenic and critically ill patients. IntJ Infect Dis. 2011, 15:e326-e331.
28. Burgos A., Zaoutis T.E., Dvorak C.C., Hoffman J.A., Knapp K.M., Nania J.J., et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008, 121:e1286-e1294.
29. Cadena J., Levine D.J., Angel L.F., Maxwell P.R., Brady R., Sanchez J.F., et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: he- patotoxicity and effectiveness. Am J Transplant. 2009, 9:2085-2091.
30. Calderon E.J., Gutierrez-Rivero S., Durand-Joly I., Dei-Cas E. Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther. 2010, 8:683-701.
31. Camara B., Martin-Blondel G., Desloques L., Ould M.A., Rouquette I., Hermant C., et al. Pneumocystisjiroveci infection associated with organizing pneumonia in a kidney transplant patient. Rev Pneumol Clin. 2010, 66:347-350.
32. Casadevall A. Fungal virulence, vertebrate endothermy, and dinosaur extinction: is there a connection?. Fungal Genet Biol. 2005, 42:98-106.
33. Cejudo M.A., Gallego A.G., Cantón-Lacasa E., Aller A.I., Romero A., Pemán-García J., et al. Evaluation of the VITEK 2 system to test the susceptibility of Candida spp., Trichosporon asahii and Cryptococcus neoformans to amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method. Med Mycol. 2010, 48:710-719.
34. Chou N.K., Chi N.H., Wu I.W., Huang S.C., Chen Y.S., Yu H.Y., et al. Fungal infection in heart transplant recipients with severe sepsis: single-center experience. Trans plant Proc. 2010, 42:952-954.
35. Clinckart F., Bulpa R., Jamart J., Eucher P., Delaunois L., Evrard P. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation. Transplant Proc. 2009, 41:607-609.
36. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Approved standard M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
37. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third informational supplement: do cument M27-S3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
38. Cortes JA, Reyes R Gomez C, Buitrago G, Leal AL. Fungal bloodstream infections in tertiary care hospitals in Colombia. Rev Iberoam Micol. 2011. En prensa.
39. Cruciani M., Mengoli C., Malena M., Bosco O., Serpelloni G., Grossi P. Antifungal pro phylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006, 12:850-858.
40. Davis J.A., Horn D.L., Marr K.A., Fishman J.A. Central nervous system involvement in cryptococcal infection in individuals after solid organ transplantation or with AIDS. Transpl Infect Dis. 2009, 11:432-437.
41. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revi sed definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative G roup and the National Institute of Allergy and Infectious Diseases Mycoses Stu dy G roup (EORTC/MSG) Consensus Gr oup. Clin Infect Dis. 2008, 46:1813-1821.
42. Eraso E., Moragues M.D., Villar-Vidal M., Sahand I.H., González-Gómez N., Pontón J., et al. Evaluation of the new chromogenic medium Candida ID 2 for isolation and identification of Candida albicans and other medically important Candida species. J Clin Microbiol. 2006, 44:3340-3345.
43. Eraso E., Ruesga M., Villar-Vidal M., Carrillo-Munoz A.J., Espinel-Ingroff A., Quindos G. Comparative evaluation of ATB Fungus 2 and Sensititre YeastOne panels for testing in vitro Candida antifungal susceptibility. Rev Iberoam Micol. 2008, 25:3-6.
44. Eraso E., Sahand I.H., Villar-Vidal M., Marcos C., Dolores M.M., Madariaga L., et al. Usefulness of Candida ID2 agar for the presumptive identification of Candida du- bliniensis. Med Mycol. 2006, 44:611-615.
45. EUCAST. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia- forming moulds. Clin Microbiol Infect. 2008; 14:982-4.
46. EUCAST EUCAST Technical Note on voriconazole. Clin Microbiol Infect. 2008, 14:985-987.
47. Eworo A., Munoz R., Yáñez J.F., Palomo J., Guembe P., Roda J., et al. Aspergilosis cardíaca en una paciente trasplantada de corazón. Rev Iberoam Micol. 2011, 28:134-138.
48. Ezzedine K., Wissing K.M., Jacobs F., Rodriguez H., Malvy D., Simonart T. Recurrent Scedosporium apiospermum skin infection in a renal transplant recipient. J Eur Acad Dermatol Venereol. 2009, 23:95-96.
49. Fortún J, Carratalá J, Gavaldá J, Lizasoain M, Salavert M, De la Cámara R, et al. Recomendaciones sobre el tratamiento de la infección fúngica invasiva por Asper gillus spp. y otros hongos filamentosos de la Sociedad Española de Microbiología Clínica y Enfermedades Infecciosas (SEIMC). Actualización 2010. Enferm Infecc Microbiol Clin. 2011; 29.[En prensa].
50. Fortún J., Martín-Dávila R., Alvarez M.E., Norman F., Sánchez-Sousa A., Gajate L., et al. False-positive results of Aspergillus galactomannan antigenemia in liver trans plant recipients. Transplantation. 2009, 87:256-260.
51. Fortún J., Martín-Dávila P., Montejo M., Munoz R., Cisneros J.M., Ramos A., et al. Pro phylaxis with caspofungin for invasive fungal infections in high-risk liver trans plant recipients. Transplantation. 2009, 87:424-435.
52. Fortún-Abete J., Martín-Dávila P. The role of anidulafungin therapy in solid organ transplant recipients. Rev Iberoam Micol. 2008, 25:129-133.
53. Fortun-Abete J. Micafungin for therapy of invasive candidiasis in solid organ transplant recipients. Rev Iberoam Micol. 2009, 26:65-68.
54. Garantziotis S., Palmer S.M. An unwelcome guest: Aspergillus colonization in lung transplantation and its association with bronchiolitis obliterans syndrome. Am J Transplant. 2009, 9:1705-1706.
55. Garcia-Solache MA, Casadevall A. Global warming will bring new fungal diseases for mammals. mBio. 2010; 1:e000061-10.
56. Greene R.E., Schlamm H.T., Oestmann J.W., Stark P., Durand C., Lortholary O., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007, 44:373-379.
57. Groll A.H., McNeil G.L. Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on In fections in the Immunocompromised Host: Thessaloniki. Greece, 22-25 June 2008. IntJAntimicrob Agents. 2009, 33:101-104.
58. Guarro J., Kantarcioglu A.S., Horre R., Rodriguez-Tudela J.L., Cuenca E.M., Berenguer J., et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refrac tory opportunist. Med Mycol. 2006, 44:295-327.
59. Guinea J., Jensen J., Pelaez T., Gijón P., Alonso R., Rivera M., et al. Value of a single galactomannan determination (Platelia) for the diagnosis of invasive aspergillo sis in non-hematological patients with clinical isolation of Aspergillus spp. Med Mycol. 2008, 46:575-579.
60. Guinea J., Recio S., Pelaez T., Torres-Narbona M., Bouza E. Clinical isolates of Asper gillus species remain fully susceptible to voriconazole in the post-voriconazole era. Antimicrob Agents Chemother. 2008, 52:3444-3446.
61. Hadley S., Huckabee C., Pappas P.G., Daly J., Rabkin J., Kauffman C.A., et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis. 2009, 11:40-48.
62. Hawksworth D.L. The magnitude of fungal diversity: the 1.5 million species esti mate revisited. Mycol Res. 2001, 105:1422-1432.
63. Hawksworth D.L. Pandora's mycological box: molecular sequences vs. morpholo gy in understanding fungal relationships and biodiversity. Rev Iberoam Micol. 2006, 23:127-133.
64. Hawksworth D.L., Rossman A.Y. Where are all the undescribed fungi?. Phytopatho logy. 1997, 87:888-891.
65. Heath C.H., Slavin M.A., Sorrell T.C., Handke R., Harun A., Phillips M., et al. Population- based surveillance for scedosporiosis in Australia: epidemiology, disease mani festations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect. 2009, 15:689-693.
66. Hofman V., Dhouibi A., Butori C., Padovani B., Gari-Toussaint M., Garcia-Hermoso D., et al. Usefulness of molecular biology performed with formaldehyde-fixed para ffin embedded tissue for the diagnosis of combined pulmonary invasive mucor- mycosis and aspergillosis in an immunocompromised patient. Diagn Pathol. 2010, 5:1.
67. Horn D., Sae-Tia S., Neofytos D. Aspergillus osteomyelitis: review of 12 cases iden tified by the Prospective Antifungal Therapy Alliance registry. Diagn Microbiol Infect Dis. 2009, 63:384-387.
68. Hosseini-Moghaddam S.M., Husain S. Fungi and molds following lung transplan tation. Semin Respir Crit Care Med. 2010, 31:222-233.
69. Husain S., Capitano B., Corcoran T., Studer S.M., Crespo M., Johnson B., et al. Intrapul- monary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation. 2010, 90:1215-1219.
70. Iversen M., Burton C.M., Vand S., Skovfoged L., Carlsen J., Milman N., et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Micro biol Infect Dis. 2007, 26:879-886.
71. Kim J.E., Sung H., Kim M.N., Won C.H., Chang S.E., Lee M.W., et al. Synchronous infection with Mycobacterium chelonae and Paecilomyces in a heart transplant patient. Transpl Infect Dis. 2011, 13:80-83.
72. Kleinschmidt-Demasters B.K. Disseminated Fusarium infection with brain absces ses in a lung transplant recipient. Clin Neuropathol. 2009, 28:417-421.
73. Kobayashi R., Kaneda M., Sato T., Ichikawa M., Suzuki D., Ariga T. The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol. 2008, 30:886-890.
74. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., et al. Pros pective surveillance for invasive fungal infections in hematopoietic stem cell trans plant recipients, 2001-2006: overview of the Transplant-Associated Infection Sur veillance Network(TRANSNET) Database. Clin Infect Dis. 2010, 50:1091-1100.
75. Lanternier F., Boutboul D., Menotti J., Chandesris M.O., Sarfati C., Mamzer Bruneel M.F., et al. Microsporidiosis in solid organ transplant recipients: two Enterocytozo- on bieneusi cases and review. Transpl Infect Dis. 2009, 11:83-88.
76. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009, 52:197-205.
77. Lass-Flörl C., Alastruey-Izquierdo A., Cuenca-Estrella M., Perkhofer S., Rodriguez- Tudela J.L. In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimi crobial susceptibility testing. Antimicrob Agents Chemother. 2009, 53:794-795.
78. Lass-Flörl C., Griff K., Mayr A., Petzer A., Gastl G., Bonatti H., et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. BrJ Haematol. 2005, 131:201-207.
79. Liu M., Worley S., Mallory G.B., Arrigain S., Robertson J., Schecter M.G., et al. Fungal infections in pediatric lung transplant recipients: colonization and invasive di sease. J Heart Lung Transplant. 2009, 28:1226-1230.
80. López García-Gallo C., García Fadul C., Laporta Hernández R., Ussetti Gil P. Traque- obronquitis aspergilar en paciente sometido a trasplante pulmonar. Rev Iberoam Micol. 2011, 28:129-133.
81. Martin S.I., Fishman J.A. Pneumocystis pneumonia in solid organ transplant reci pients. Am J Transplant. 2009, 9(Suppl 4):S227-S233.
82. McNeil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001, 33:641-647.
83. Mengoli C., Cruciani M., Barnes R.A., LoefflerJ, Donnelly J.P. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis. 2009, 9:89-96.
84. Miceli M.H., Diaz J.A., Lee S.A. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011, 11:142-151.
85. Monforte V., Ussetti P., Gavalda J., Bravo C., Laporta R., Len O., et al. Feasibility, tolera- bility, and outcomes of nebulized liposomal amphotericin B for Aspergillus infec tion prevention in lung transplantation. J Heart Lung Transplant. 2010, 29:523-530.
86. Morgan J., Wannemuehler K.A., Marr K.A., Hadley S., Kontoyiannis D.P., Walsh T.J., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005, 43(Suppl 1):S49-S58.
87. Morio F., Horeau-Langlard D., Gay-Andrieu F., Talarmin J.P., Haloun A., Treilhaud M., et al. Disseminated Scedosporium/Pseudallescheria infection after double- lung transplantation in patients with cystic fibrosis. J Clin Microbiol. 2010, 48:1978-1982.
88. Neofytos D., Fishman J.A., Horn D., Anaissie E., Chang C.H., Olyaei A., et al. Epidemio logy and outcome of invasive fungal infections in solid organ transplant reci pients. Transpl Infect Dis. 2010, 12:220-229.
89. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemio logy and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009, 48:265-273.
90. Nivoix Y., Velten M., Letscher-Bru V., Moghaddam A., Natarajan-Ame S., Fohrer C., et al. Factors associated with overall and attributable mortality in invasive aspergi llosis. Clin Infect Dis. 2008, 47:1176-1184.
91. Osawa R., Alexander B.D., Forrest G.N., Lyon G.M., Somani J., Del Busto R., et al. Geo graphic differences in disease expression of cryptococcosis in solid organ trans plant recipients in the United States. Ann Transplant. 2010, 15:77-83.
92. Pagano L., Caira M., Candoni A., Offidani M., Fianchi L., Martino B., et al. The epide miology of fungal infections in patients with hematologic malignancies: the SEI- FEM-2004 study. Haematologica. 2006, 91:1068-1075.
93. Panackal A.A., Li H., Kontoyiannis D.P., Mori M., Perego C.A., Boeckh M., et al. Geocli- matic influences on invasive aspergillosis after hematopoietic stem cell trans plantation. Clin Infect Dis. 2010, 50:1588-1597.
94. Pappas P.G., Alexander B.D., Andes D.R., Hadley S., Kauffman C.A., Freifeld A., et al. In vasive fungal infections among organ transplant recipients: results of the Trans plant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010, 50:1101-1111.
95. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48:503-535.
96. Pappas P.G., Silveira F.P. Candida in solid organ transplant recipients. Am J Trans plant. 2009, 9(Suppl 4):S173-S179.
97. Pasqualotto A.C., Xavier M.O., Sanchez L.B., De Oliveira Costa C.D., Schio S.M., Camargo S.M., et al. Diagnosis of invasive aspergillosis in lung transplant recipients by de tection of galactomannan in the bronchoalveolar lavage fluid. Transplantation. 2010, 90:306-311.
98. Pazos C., Moragues M.D., Quindos G., Ponton J., Del P.A. Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diag nosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol. 2006, 23:209-215.
99. Pazos C., Pontón J., Del Palacio A. Contribution of (1->3)-beta-D-glucan chromoge- nic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005, 43:299-305.
100. Peman J., Canton E., Camarena Minana J.J., Alcoba F.J., EcheverriaJ, Navarro O.D., et al. Variation in fungemia epidemiology and fluconazole susceptibility in Spain in the last 10 years: results from FUNGEMYCA study. Rev Iberoam Micol. 2011, 28:91-99.
101. Pemán J., Zaragoza R., Quindós G., Alkorta M., Cuétara M.S., Camarena J.J., et al. Clini cal factors associated with a Candida albicans germ tube antibody positive test in Intensive Care Unit patients. BMC Infect Dis. 2011, 11:60.
102. Perfect J.R., Dismukes W.E., Dromer F., Goldman D.L., Graybill J.R., Hamill R.J., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010, 50:291-322.
103. Pfaller M., Boyken L., Hollis R., Kroeger J., Messer S., Tendolkar S., et al. Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for tes ting itraconazole, posaconazole, and voriconazole against Aspergillus isolates. J Clin Microbiol. 2011, 49:1110-1112.
104. Pfaller M.A., Castanheira M., Diekema D.J., Messer S.A., Moet G.J., Jones R.N. Compari son of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol. 2010, 48:1592-1599.
105. Pfaller M.A., Diekema D.J., Ghannoum M.A., Rex J.H., Alexander B.D., Andes D., et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fu- migatus and three triazoles as determined by the Clinical and Laboratory Stan dards Institute broth microdilution methods. J Clin Microbiol. 2009, 47:3142-3146.
106. Pongas G.N., Lewis R.E., Samonis G., Kontoyiannis D.P. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. Clin Microbiol Infect. 2009, 15(Suppl 5):93-97.
107. Ponton J. Usefulness of biological markers in the diagnosis of invasive candidia- sis. Rev Iberoam Micol. 2009, 26:8-14.
108. Pozo-LaderasJC, Pontes-Moreno A. Candidiasis invasora en receptor de trasplan- te hepático: tratamiento antifúngico de rescate precoz. Rev Iberoam Micol. 2011, 28:124-128.
109. Quindós G. New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi. Clin Microbiol Infect. 2006, 12(Suppl 7):40-52.
110. Quindós G. Nosocomial candidemias and invasive candidiasis. Med Clin (Barc). 2010, 134:17-19.
111. Quindós G., Carrillo-Muñoz A.J., Eraso E., Cantón E., Pemán J. In vitro antifungal ac tivity of voriconazole: New data after the first years of clinical experience. Rev Iberoam Micol. 2007, 24:198-208.
112. Quindós G., Eraso E. In vitro antifungal activity of anidulafungin. Rev Iberoam Micol. 2008, 25:83-91.
113. Quindós G., Eraso E., Carrillo-Muñoz A.J., Cantón E., Pemán J. In vitro antifungal ac tivity of micafungin. Rev Iberoam Micol. 2009, 26:35-41.
114. Quindós G., Sánchez-Vargas L.O., Villar-Vidal M., Eraso E., Alkorta M., Hernández- Almaraz J.L. Activities of fluconazole and voriconazole against bloodstream isola tes of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Int J Antimicrob Agents. 2008, 31:266-271.
115. Rees J.R., Pinner R.W., Hajjeh R.A., Brandt M.E., Reingold A.L. The epidemiological fea tures of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998, 27:1138-1147.
116. Rekha A., Kindo A.J., Sounderarajan R., Ravi A. Infection with Histoplasma capsula- tum in a renal transplant recipient. Saudi J Kidney Dis Transpl. 2010, 21:1115-1117.
117. Richardson M., Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008, 14(Suppl 4):5-24.
118. Rodriguez-Tudela J.L., Arendrup M.C., Cuenca-Estrella M., Donnelly J.P., Lass-Florl C. EUCAST breakpoints for antifungals. Drug News Perspect. 2010, 23:93-97.
119. Rodriguez-Tudela J.L., Berenguer J, Guarro J, Kantarcioglu A.S., Horre R., De Hoog GS, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol. 2009, 47:359-370.
120. Ruiz-Camps I., Aguado J.M., Almirante B., Bouza E., Ferrer B.C., Len O., et al. Recom mendations of the Spanish Society of Infectious Diseases and Clinical Microbio logy (SEIMC) on the prevention of invasive fungal infection due to filamentous fungi. Enferm Infecc Microbiol Clin. 2010, 28:172.
121. Ruiz-Herrera J., Ortiz-Castellanos L. Analysis of the phylogenetic relationships and evolution of the cell walls from yeasts and fungi. FEMS Yeast Res. 2010, 10:225-243.
122. Ruping M.J., Heinz W.J., Kindo A.J., Rickerts V., Lass-Florl C., Beisel C., et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010, 65:296-302.
123. Sahand I.H., Moragues M.D., Eraso E., Villar-Vidal M., Quindos G., Ponton J. Supple mentation of CHROMagar Candida medium with Pal's medium for rapid identifi cation of Candida dubliniensis. J Clin Microbiol. 2005, 43:5768-5770.
124. Segal B.H. Aspergillosis. N EnglJ Med. 2009, 360:1870-1884.
125. Sharifipour F., Rezaeetalab F., Naghibi M. Pulmonary fungal infections in kidney transplant recipients: an 8-year study. Transplant Proc. 2009, 41:1654-1656.
126. Shoham S., Hinestrosa F., Moore J., O'Donnell S., Ruiz M., Light J. Invasive filamen tous fungal infections associated with renal transplant tourism. Transpl Infect Dis. 2010, 12:371-374.
127. Silveira F.P., Husain S. Fungal infections in solid organ transplantation. Med Mycol. 2007, 45:305-320.
128. Silveira F.P., Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med. 2008, 14:211-218.
129. Singh N., Aguado J.M., Bonatti H., Forrest G., Gupta K.L., Safdar N., et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to antrecipients:aprospective,matchedcase-controlstudytoassess risks for disease and outcome. J Infect Dis. 2009, 200:1002-1011.
130. Singh N., Husain S. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant. 2009, 9(Suppl 4):S180-S191.
131. Sipsas N.V., Kontoyiannis D.P. Occupation, lifestyle, diet, and invasive fungal infec tions. Infection. 2008, 36:515-525.
132. Solé A. Infección diseminada por Scedosporium apiospermum en un receptor de trasplante pulmonar unilateral. Rev Iberoam Micol. 2011, 28:139-142.
133. Steinmann J., Buer J., Rath P.M., Paul A., Saner F. Invasive aspergillosis in two liver transplant recipients: diagnosis by SeptiFast. Transpl Infect Dis. 2009, 11:175-178.
134. Vehreschild J.J., Ruping M.J., Steinbach A., Cornely O.A. Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. Expert Opin Pharmacother. 2010, 11:95-113.
135. Von Lilienfeld-Toal M., Lehmann L.E., Raadts A.D., Hahn-Ast C., Orlopp K.S., Marklein G., et al. Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J Clin Microbiol. 2009, 47:2405-2410.
136. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008, 46:327-360.
137. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Noso comial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004, 39:309-317.
138. Woo P.C., Lau S.K., Ngan A.H., Tung E.T., Leung S.Y., To K.K., et al. Lichtheimia hongkongen- sis sp. nov., a novel Lichtheimia spp. associated with rhinocerebral, gastrointestinal, and cutaneous mucormycosis. Diagn Microbiol Infect Dis. 2010, 66:274-284.
139. Zaoutis T.E., Heydon K., Chu J.H., Walsh T.J., Steinbach W.J. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the Uni ted States, 2000. Pediatrics. 2006, 117:e711-e716.